DB-1303 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Vaginal Cancer. According to GlobalData, Phase II drugs for Vaginal Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DB-1303’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DB-1303 is under development for the treatment of advanced/unresectable, recurrent, or metastatic HER2-expressing malignant solid tumors, ovarian cancer, recurrent or metastatic endometrial carcinoma with HER2 overexpression, gastric, esophageal cancer, adenocarcinoma of the gastroesophageal junction, colorectal cancer, human epidermal growth factor receptor 2 positive breast cancer (her2 positive breast cancer), metastatic breast cancer, vaginal cancer, non-small cell lung cancer, adenocarcinoma . It is administered through intravenous route of administration. It is being developed based on DITAC platform. It acts by targeting Her2 expressing tumor cells and DNA topoisomerase I (Top I).
Duality Biologics (Shanghai) overview
Duality Biologics (Shanghai) is a company focusing on the development, commercialization and discovery of new modality biologics to provide solutions. The company is headquartered in Shanghai, China.
For a complete picture of DB-1303’s drug-specific PTSR and LoA scores, buy the report here.